Steatotic Liver Disease in Austria: A Long-Term Registry and Biobank

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

SLD-AT is a multicenter, prospective observational registry with an accompanying biobank, enrolling about 20,000 adults over 15 years to study epidemiology, progression, and prognosis. It collects baseline and follow-up data on clinical, laboratory, imaging, and treatment-related factors, including non-invasive fibrosis and steatosis assessments. The study will document liver-related complications, cardiovascular events, malignancies, and mortality, aiming to identify predictors of progression and validate diagnostic tools in real-world care. No experimental treatments are introduced; patient management follows standard clinical practice. Biological samples will be stored for future biomarker research to support ongoing analyses.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\. Age 18-100 years.
* 2\. Suspected steatotic liver disease (SLD), defined by at least one of the following criteria:
* Suspected SLD based on previous medical findings.
* Evidence of hepatic steatosis assessed by, Controlled attenuation parameter (CAP), Ultrasound, Magnetic resonance imaging (MRI), or Liver histology
* Suspected advanced liver fibrosis assessed by Vibration-controlled transient elastography (VCTE; ≥8 kPa), Ultrasound, Magnetic resonance elastography (MRE), or Liver histology
* Elevated liver enzymes (AST, ALT, and/or GGT) within 6 months prior to enrollment.
* 3\. Written informed consent to participate in the registry.

Exclusion Criteria:

* Withdrawal of written informed consent.
* Diagnosis of any of the following active chronic liver diseases:
* Chronic hepatitis B
* Chronic hepatitis C
* Autoimmune or cholestatic liver disease
* Genetic liver disease
* Current diagnosis of alcohol-associated hepatitis.
* Current decompensated liver cirrhosis.

Where it's running

• Medical University of Vienna
  Vienna, State of Vienna, Austria Recruiting

Study contacts

• Study coordinator: Georg Semmler, MD PhD
• Email: sld@meduniwien.ac.at
• Phone: +4314040047410

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Large language model chatbot to help people with metabolic alcohol-related liver disease cut back on drinking

  This pilot will test whether a WhatsApp-based large language model chatbot can help adults in Hong Kong with metabolic alcohol-related liver disease drink less alcohol.

  Recruiting The University of Hong Kong · Hong Kong · NCT07450144

• Health profile of MASLD in Kazakhstan and real-world use of Ursosan in Almaty

  This study tests how MASLD appears in adults in Kazakhstan and how Ursosan is used in real-world care for a subgroup in Almaty.

  Recruiting at 7 sites Kazakh Association of Internal Medicine Specialists · Aktobe, Aktobe and 6 other locations · NCT07889999

• Endohepatology-based reclassification of treatment indication in high-risk MASLD

  This study tests whether an endohepatology assessment can change treatment decisions for adults with high-risk MASLD.

  Recruiting University Hospital Muenster · Münster · NCT07877272

• ALN-CIDEB in adults with MASLD to see if it helps the liver

  This study tests whether ALN-CIDEB can help adults with MASLD and its liver damage compared to placebo.

  Recruiting at 4 sites Phase 3 Regeneron Pharmaceuticals · Miami, Florida and 3 other locations · NCT07854782

• Liver Fat and Scarring in People Suspected of Non-Celiac Wheat Sensitivity

  This study looks to see if people with non-celiac wheat sensitivity have liver fat or fibrosis and how this relates to IBS/FD and celiac disease.

  Recruiting at 2 sites University of Palermo · Palermo, Palermo and 1 other locations · NCT07750535

• Taiwan green propolis for MASLD and lipid/metabolic issues

  This study tests whether Taiwan green propolis capsules can improve blood lipids and body fat in adults with MASLD compared to a placebo over 12 weeks.

  Recruiting Taipei Medical University · Dalin · NCT07692438

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.